Takeda's second bet on DARTs

MacroGenics and Takeda agreed to co-develop four product candidates using the biotech's Dual-Affinity Re-Targeting (DART) platform. MacroGenics, located in Rockville, Maryland, has created over 100 DART molecules, which target multiple antigens or cells using a single, antibody-like molecule. The recent $400-million deal includes four DART-based product candidates for autoimmune disorders. This is Takeda's second alliance with MacroGenics this year. The first was in May when Osaka, Japan–based Takeda licensed MGD010, a bispecific antibody against CD32B and CD79B, following a phase 1a trial in an autoimmune disorder.